Cochrane · systematic review · CD011293

Sublingual immunotherapy for asthma

Fortescue, R, Kew, KM, Leung, MShiu Tsun · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library

Airways2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 2 · 28.6%Low 2 · 28.6%Moderate 1 · 14.3%High 1 · 14.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Sublingual immunotherapy versus control for asthma

Population: adults and children with asthma
7 questions
OutcomeEffectEvidenceStatus / GRADE
Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks
Sublingual immunotherapy vs control
OR 0.35 [0.1, 1.2]2 studies · 108 participantsVery low
Downgraded: imprecision, indirectness, publication bias
Quality of life
Sublingual immunotherapy vs control
no estimate extractedNRNo studies
Serious adverse events Weighted mean duration of studies: 56 weeks
Sublingual immunotherapy vs control
no estimate extracted29 studies · 4810 participantsModerate
Downgraded: risk of bias, indirectness
Exacerbation requiring OCS Weighted mean duration of studies: 58 weeks
Sublingual immunotherapy vs control
OR 0.75 [0.45, 1.24]5 studies · 1364 participantsVery low
Downgraded: imprecision, indirectness, publication bias
All adverse events Weighted mean duration of studies: 62 weeks**
Sublingual immunotherapy vs control
OR 1.99 [1.49, 2.67]27 studies · 4251 participantsHigh
Bronchial provocation
Sublingual immunotherapy vs control
no estimate extracted5 studies · 200 participantsLow
Downgraded: risk of bias, imprecision, inconsistency
ICS use
Sublingual immunotherapy vs control
no estimate extracted3 studies · 778 participantsLow
Downgraded: imprecision, indirectness